Immunodeficiency 27a
Disease Details
Family Health Simplified
- Description
-
Immunodeficiency-27a, also known as Immunodeficiency Common Variable Type 10 (CVID10), is a genetic disorder characterized by low levels of serum immunoglobulins and increased susceptibility to infections.
One-sentence description: Immunodeficiency-27a is a genetic disorder that results in low serum immunoglobulin levels and heightened vulnerability to infections. - Type
- Immunodeficiency-27A (IMD27A) is a type of primary immunodeficiency disorder. It is transmitted in an autosomal recessive manner.
- Signs And Symptoms
-
Immunodeficiency 27A, also known as Immunodeficiency with Hyper-IgM type 3 (HIGM3), is a rare genetic disorder characterized by an increased susceptibility to infections and an impaired immune response. Here's an overview:
**Signs and Symptoms:**
1. Frequent and recurrent bacterial, viral, and fungal infections.
2. Chronic diarrhea.
3. Failure to thrive in infancy.
4. Lymphoid hyperplasia (enlarged lymph nodes).
5. Pneumocystis jirovecii pneumonia (PCP).
6. Reduced levels of immunoglobulin G (IgG) and immunoglobulin A (IgA).
7. Elevated levels of immunoglobulin M (IgM).
8. Autoimmune diseases.
Regular monitoring and treatment are essential for managing this condition, often involving immune globulin replacement therapy and prophylactic antibiotics. - Prognosis
-
Immunodeficiency 27a is a very rare primary immunodeficiency disorder. Prognosis can vary depending on the severity of the condition and how it is managed. Early diagnosis and appropriate medical intervention, including immunoglobulin replacement therapy and antibiotic prophylaxis, can improve outcomes. However, patients are generally at increased risk for recurrent infections, autoimmune complications, and other related health issues throughout their lives.
"Nan" stands for "Nanodysplasia-Anemia-Neutropenia syndrome."
If you need more specific details or have another question, please let me know. - Onset
- Immunodeficiency-27A typically presents in infancy or early childhood.
- Prevalence
- Immunodeficiency_27A (IMD27A) is an extremely rare genetic condition. There is insufficient data to accurately describe its prevalence, often categorized as "nan" (not a number) due to the scarcity of reported cases.
- Epidemiology
- Immunodeficiency-27A, also known as Immunodeficiency Common Variable Type 27 (CVID27), is a rare genetic disorder that affects the immune system. Due to its rarity, specific epidemiological data such as prevalence and incidence rates are not widely documented. However, primary immunodeficiency disorders like CVID generally occur in both males and females and can present at any age, though they are often diagnosed in adulthood. There is no significant data showing a higher prevalence in specific geographical regions or ethnic groups.
- Intractability
-
Immunodeficiency_27a (IMD27A), also known as the RASGRP1 deficiency, is a primary immunodeficiency disorder caused by mutations in the RASGRP1 gene. It presents with a range of symptoms due to impaired immune function, and the severity can vary among individuals. Management typically includes supportive care and treatments aimed at preventing and managing infections, as well as potential immunoglobulin replacement therapy.
While IMD27A is currently considered challenging to cure due to its genetic basis, advances in gene therapy and other emerging treatments might provide future options. Therefore, it is not entirely intractable, but it remains difficult to manage comprehensively with current medical interventions. - Disease Severity
- Immunodeficiency-27A (IMD27A) is typically characterized by mild to moderate disease severity. It presents primarily with recurrent bacterial and viral infections due to the body's compromised ability to fight off pathogens.
- Healthcare Professionals
- Disease Ontology ID - DOID:0111955
- Pathophysiology
- Immunodeficiency-27A is caused by mutations in the gene encoding the phosphoinositide 3-kinase (PI3K) regulatory subunit 1. This leads to a disrupted PI3K-AKT signaling pathway, which is essential for the development, function, and survival of B cells and T cells. Consequently, this causes a range of immune system malfunctions, including reduced production of immunoglobulins, poor antibody responses, and recurrent infections. The specific details regarding "nan" are unclear without additional context.
- Carrier Status
- It appears that there may be some confusion or a typo in your query, as "immunodeficiency_27a" doesn't correspond to a recognized term or specific condition in medical literature. Could you please provide more specific details or check for any errors in the name of the disease?
- Mechanism
-
Immunodeficiency 27A, also known as Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), is primarily caused by gain-of-function mutations in the PIK3CD gene. This gene encodes the catalytic subunit p110δ of the phosphoinositide 3-kinase (PI3K) enzyme, which plays a crucial role in the immune system by regulating the development, activation, and survival of lymphocytes.
**Mechanism:**
The aberrant activation of the PI3K pathway due to these mutations results in hyperactivation of downstream signaling pathways, particularly the AKT/mTOR pathway. This leads to an abnormal immune response, characterized by:
1. **Impaired Lymphocyte Function**: Overactive PI3K signaling disrupts normal B cell and T cell functions, causing them to proliferate excessively but function poorly.
2. **Dysregulated Immune Responses**: The defective regulation of immune responses can lead to immunodeficiency, where the body is less capable of fighting infections, and potentially autoimmunity or lymphoproliferative disorders.
**Molecular Mechanisms:**
1. **Gain-of-function Mutations**: The PIK3CD gene mutations often result in a change in the protein structure of p110δ, leading to its constitutive activation.
2. **PI3K-AKT Pathway Activation**: Constant activation of PI3K promotes the phosphorylation and activation of AKT, a key intracellular signaling molecule.
3. **mTOR Signaling**: Activated AKT subsequently upregulates the mTOR pathway, crucial for cell growth and survival. Overactivation of mTOR alters normal cell cycle regulation and cellular metabolism.
4. **Altered Cellular Functions**: These molecular changes impact crucial immune cell functions such as proliferation, differentiation, and survival, leading to the immunodeficiency phenotype seen in APDS patients.
Overall, the gain-of-function mutations in PIK3CD lead to an overactive PI3K signaling pathway, resulting in compromised immune regulation and function, which characterizes immunodeficiency 27A. - Treatment
-
Immunodeficiency 27A is a rare genetic condition characterized by a weakened immune system. Treatment typically focuses on managing infections and preventing complications. This may include:
1. **Antibiotics or antiviral medications:** To treat or prevent infections.
2. **Immunoglobulin replacement therapy:** To boost the immune system if the body doesn't produce enough antibodies.
3. **Hematopoietic stem cell transplant (HSCT):** In severe cases, a bone marrow transplant may be considered to reconstitute the immune system.
4. **Regular monitoring:** Frequent medical check-ups to promptly address any emerging health issues.
Specialists like immunologists often oversee the treatment plan, tailoring therapies to the individual's specific condition and needs. - Compassionate Use Treatment
-
Immunodeficiency 27A (IMD27A), caused by mutations in the gene encoding the protein DOCK8, often requires treatments that go beyond conventional approaches due to its severe nature. For compassionate use or off-label experimental treatments, a few options have been explored:
1. **Allogeneic Hematopoietic Stem Cell Transplantation (HSCT):** HSCT is considered the most definitive treatment and has been used successfully in severe cases. This procedure involves the transplantation of stem cells from a healthy donor to replace the defective immune system.
2. **Gene Therapy:** Although still largely experimental, gene therapy aims to correct the underlying genetic defect. This can involve inserting a correct copy of the gene into the patient's hematopoietic stem cells.
3. **Interferon Gamma (IFN-γ):** This cytokine has been used off-label to enhance immune response and reduce infections. However, it does not correct the underlying genetic defect.
4. **Targeted Immunoglobulin Replacement Therapy:** Immunoglobulin replacement therapy is commonly used to reduce the frequency and severity of infections. While this doesn't address the primary genetic cause, it supports the immune system.
These treatments are typically considered on a case-by-case basis, weighing the potential benefits and risks, especially given the limited experience and regulatory considerations associated with compassionate use and off-label applications. - Lifestyle Recommendations
-
Immunodeficiency 27A is a rare genetic disorder affecting the immune system, which can lead to increased susceptibility to infections. Here are some lifestyle recommendations:
1. **Infection Prevention**:
- Practice good hygiene, such as regular hand washing.
- Avoid crowds and contact with sick individuals.
- Keep vaccinations up to date as recommended by healthcare providers.
2. **Healthy Diet**:
- Follow a balanced diet rich in fruits, vegetables, and lean proteins to support overall health.
- Avoid undercooked or raw foods that may carry bacteria or parasites.
3. **Regular Medical Checkups**:
- Maintain regular appointments with healthcare providers to monitor and manage the condition.
- Promptly address any signs of infection or other health concerns with a healthcare professional.
4. **Exercise**:
- Engage in regular, moderate physical activity to improve overall health and well-being, but consult with a healthcare provider to tailor the exercise regimen to individual capabilities.
5. **Stress Management**:
- Practice stress-reducing techniques such as mindfulness, meditation, or yoga.
- Ensure adequate sleep and rest.
6. **Avoid Smoking and Limit Alcohol**:
- Avoid exposure to tobacco smoke.
- Limit alcohol consumption as it can weaken the immune system.
These lifestyle recommendations aim to enhance overall health and minimize the risk of infections for individuals with Immunodeficiency 27A. - Medication
- Immunodeficiency-27a, also known as autosomal recessive Agammaglobulinemia-7, is a rare genetic disorder affecting the immune system. There is no medication listed as "nan" for this condition. Treatments typically involve immunoglobulin replacement therapy to provide the necessary antibodies that the patient’s body cannot produce. Furthermore, antibiotics may be prescribed to prevent or treat infections. Patients should work closely with a healthcare provider to develop an appropriate treatment plan tailored to their specific needs.
- Repurposable Drugs
- Immunodeficiency 27A (IMD27A) is often associated with mutations in the FCGR3A gene. There are no well-established repurposable drugs specifically for treating this condition. Management typically involves general approaches to boost the immune system and prevent infections, such as immunoglobulin replacement therapy and prophylactic antibiotics. Consultation with a healthcare professional is crucial for personalized management strategies.
- Metabolites
-
For immunodeficiency_27a (IMD27A), it would be essential to focus on metabolic alterations and quantifiable laboratory findings:
- **Metabolites:** Elevated levels of citrulline are characteristic of immunodeficiency_27a. This elevation is due to mutations in the ORAI1 gene, which can affect calcium influx in cells and subsequently impact the urea cycle, leading to the accumulation of citrulline.
- **Nan:** Nan (Not applicable/Not available) may refer to data or aspects not currently well-documented or relevant, such as the direct impact of nanotechnology on the condition or lack of specific nanomaterial therapeutics for IMD27A at this time.
These points are crucial in understanding and diagnosing IMD27A. - Nutraceuticals
-
Immunodeficiency-27A is a primary immunodeficiency disorder caused by mutations in the LIG4 gene, which codes for ligase IV, a crucial component in DNA repair mechanisms. Patients with this condition often have features such as microcephaly, developmental delay, and heightened sensitivity to ionizing radiation, along with immunodeficiency.
As for nutraceutical support, while specific scientific evidence for nutrition-based treatments in immunodeficiency-27A is limited, maintaining overall immune health can benefit from certain nutritional approaches:
1. **Vitamins and Minerals:** Ensure sufficient intake of vitamins A, C, D, E, B6, B12, folate, zinc, iron, selenium, and copper, which are crucial for immune function.
2. **Omega-3 Fatty Acids:** Found in fish oil, these can help modulate inflammation and support immune health.
3. **Probiotics:** Beneficial bacteria that support gut health, indirectly supporting immune function.
4. **Antioxidants:** Consuming foods rich in antioxidants can help mitigate oxidative stress, which is critical due to the impaired DNA repair mechanisms in these patients.
Scientific evidence directly linking these nutraceuticals to the treatment of immunodeficiency-27A specifically is limited and should be approached with caution and in consultation with healthcare professionals.
In connection to nanotechnology (abbreviated as "nan"), there's currently no specific application of nanotechnology targeting immunodeficiency-27A. However, ongoing research in nanomedicine aims to develop targeted drug delivery systems, nanoscale vaccines, and gene therapy mechanisms that may offer future treatment possibilities for various genetic disorders, including immunodeficiency conditions. - Peptides
-
Immunodeficiency 27A (IMD27A) is a genetic disorder characterized by susceptibility to infections due to a compromised immune system. It is caused by mutations in the SPPL2A gene.
Regarding peptides, there is no widely recognized peptide treatment specifically for IMD27A. Research in peptide therapy for immunodeficiencies is ongoing, and advancements might lead to future therapeutic options.
Nanotechnology, on the other hand, holds promise for the diagnosis and treatment of immunodeficiencies, including potentially improved vaccine delivery systems, targeted drug delivery, and advanced diagnostic techniques. However, specific nano-based therapies for IMD27A are not yet established in clinical practice.